CPA
CRBP icon

Capital Performance Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Capital Performance Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3
Closed -$62 – 729
2024
Q3 		$62 Buy
+3
New +$154 ﹤0.01% 2770

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Performance Advisors's CRBP Position: Q4 2024 in Review

Capital Performance Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q4 2024, closing a stake of 3 shares — an estimated $62 sold.

Capital Performance Advisors first reported a position in CRBP in Q3 2024 and held it in 1 quarter. The position peaked at $62 in Q3 2024. 99 funds tracked by Wall St. Rank hold CRBP as of Q4 2024.

  • Capital Performance Advisors reported no remaining Corbus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 3 Corbus Pharmaceuticals shares in Q4 2024, an estimated $62.
  • Capital Performance Advisors first reported a position in Corbus Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Corbus Pharmaceuticals position peaked at $62 in Q3 2024.
  • 99 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.